Sunday June 3 Press Briefing: ASCO Press Releases with links to abstracts

Immunotherapy Pembrolizumab Works Better Than Chemotherapy Alone as Initial Treatment for Most Advanced Lung Cancers

 “Immunotherapy with pembrolizumab alone benefits a much larger number of patients than we had previously thought. This is yet another promising result with immunotherapy in lung cancer that brings new momentum to the treatment of this notoriously difficult disease,” said ASCO Expert John Heymach, MD, PhD. 

CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT

 

Maintenance Chemotherapy Extends Life for Children With a Rare Cancer – First Treatment Advance for This Cancer in 30 Years

 “By keeping the pressure on this cancer longer with maintenance therapy, we are giving patients two wins – we are boosting cure rates by preventing relapses and doing so with few serious side effects. After three decades of research, this finding goes to show that we will continue innovating treatment, no matter how long it takes,” said ASCO Expert Warren Chow, MD. 

CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT

 

Most Women With Early Stage Breast Cancer Can Forgo Chemotherapy When Guided by a Diagnostic - Test Test of 21-Tumor Genes Helps Tailor Treatment Decisions Summary includes data not in the abstract

 “This study, which never would have happened without federal funding for cancer research, will transform care immediately, and for the better. These data provide critical reassurance to doctors and patients that they can use genomic information to make better treatment decisions in women with early-stage breast cancer. Practically speaking, this means that thousands of women will be able to avoid chemotherapy, with all of its side effects, while still achieving excellent long-term outcomes,” said ASCO Expert Harold Burstein, MD, PhD, FASCO. 

CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT

CLICK TO SEE PUBLICATION IN THE NEJM

Click to see the corresponding article in the New York Times

 

Phase III Trial Finds Many People With Advanced Kidney Cancer Do Not Need Surgery

 “Thanks to this research, many patients with advanced kidney cancer can be spared unnecessary surgery and a host of severe side effects that often accompany it. These findings will likely lead to a dramatic change in treatment for people who are diagnosed with metastatic kidney cancer,” said ASCO Expert Sumanta K. Pal, MD. 

CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT